Award-winning ovarian cancer diagnostic firm secures seed funding

Award-winning ovarian cancer diagnostic company GenoME Diagnostics, a spin out from Queen’s University Belfast, has secured £300,000 following a successful seed funding round.

Wednesday, 9th June 2021, 5:00 pm

Supported by QUBIS, the commercialisation arm of Queen’s University, Deepbridge Capital and Co-Fund NI which is part of Invest Northern Ireland’s Access to Finance portfolio, the money will assist the firm with its research.

GenoME Diagnostics specialises in developing novel blood tests for the earlier and more accurate diagnosis of ovarian cancer, utilizing cutting-edge technology to provide user-friendly and cost-effective diagnostics to reduce misdiagnosis and late diagnosis of the disease.

The Company was created as a result of almost a decade of research by Dr Paul Mullan Dr James Beirne and Dr Laura Feeney at the Patrick G Johnston Centre for Cancer Research (PGJCCR) at Queen’s University. Dr Shannon Beattie joined the team and was selected to participate in the Innovate UK ‘Innovation to Commercialisation of University Research (ICURe) programme’ in 2019. This led to a successful application for Innovate UK funding and the formation of the company. In 2020 the company was crowned the All Ireland Best New Start Company in the Intertrade Ireland Seedcorn competition.

Sign up to our daily newsletter

The i newsletter cut through the noise

Dr Paul Mullan, Co-Founder of GenoME Diagnostics, CEO of QUBIS Brian McCaul, Enterprise Network Manager at QUBIS Anne Dornan, Stuart Gaffikin Investment Manager at Co Fund NI, Co-Founder and Chief Medical Officer of GenoMe Diagnostics Dr James Beirne, GenoME Diagnostics COO Dr Shannon Beattie

Dr Shannon Beattie, COO of GenoME Diagnostics, said: “Our work benefits women who are at risk of developing ovarian cancer, or who present with possible symptoms. Early diagnosis can ultimately save lives, as well as reduce cost pressures for healthcare providers. We also aim to benefit clinical trial providers and drug developers, by developing accurate and cost-effective companion diagnostics, to better stratify patients and increase their chance of response to novel therapies.”

Co-Founder, Dr Paul Mullan, continued; “Ovarian cancer is often dubbed ‘the silent killer’ due to the non-specific symptoms of this disease and the sub-optimal diagnostic tests. It is often only diagnosed in the later stages of the disease when it has already spread, with around 75% of women diagnosed in the later stages of disease. Earlier diagnosis of ovarian cancers could potentially dramatically increase patient survival, by catching tumours when they are small and less likely to have spread, or have developed resistance to chemotherapy.”

Anne Dornan, Enterprise Network Manager at QUBIS, explained: “GenoME Diagnostics builds on 10 years of research at Queen’s and the team has made great progress on their commercialisation journey. GenoME has the potential to improve outcomes for women at risk of developing ovarian cancer across the globe, QUBIS along with the other funders involved, look forward to supporting the company through its early-stage development, and wish the team every success for the future.”

Ben Carter, Investment Manager at Deepbridge Capital, added: “We are delighted to be supporting the GenoME team develop and commercialise this exciting and important work, via the Deepbridge Life Sciences SEIS. GenoME has a remarkable founding team and is supported by excellent science and research, meaning the Company represents exactly the type of innovative Company that the Seed Enterprise Investment Scheme is designed to help fund.“

Co-Fund NI is part of Invest NI’s Access to Finance portfolio and part funded by European Regional Development Fund under the EU Investment for Growth and Jobs Programme 2014-2020. Clarendon Fund Managers manages Co-Fund NI.

A message from the Editor:

Thank you for reading this story on our website. While I have your attention, I also have an important request to make of you.

In order for us to continue to provide high quality and trusted local news on this free-to-read site, I am asking you to also please purchase a copy of our newspaper whenever you are able to do so.

Our journalists are highly trained and our content is independently regulated by IPSO to some of the most rigorous standards in the world. But being your eyes and ears comes at a price. So we need your support more than ever to buy our newspapers during this crisis.

With the coronavirus lockdown having a major impact on many of our local valued advertisers - and consequently the advertising that we receive - we are more reliant than ever on you helping us to provide you with news and information by buying a copy of our newspaper when you can safely.

You can also enjoy unlimited access to the best news from across Northern Ireland and the UK by subscribing to newsletter.co.uk

With a digital subscription, you can read more than five articles, see fewer ads, enjoy faster load times, and get access to exclusive newsletters and content. Visit https://www.newsletter.co.uk/subscriptions now to sign up.

Thank you